The Effects of Cyclooxygenase Isozyme Inhibition onIncisional Wound Healing in Mouse Skin  by Müller-Decker, Karin et al.
ORIGINAL ARTICLE
See related Commentary on page 985
The E¡ects of Cyclooxygenase Isozyme Inhibition on
Incisional Wound Healing in Mouse Skin
Karin Mˇller-Decker,Wolfgang Hirschner, Friedrich Marks, and Gerhard Fˇrstenberger
Deutsches Krebsforschungszentrum, Research ProgramTumor Cell Regulation, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany
In addition to their proin£ammatory activities, prosta-
glandins recently have been shown to be bene¢cial
in the resolution of tissue injury and in£ammation.
Thus, inhibition of cyclooxygenase-2, the predominant
prostaglandin endoperoxide synthase under these
conditions, may not only result in attenuating
the in£ammatory response but also in delaying tissue
regeneration and repair. To this end, we investigated
cyclooxygenase isozyme expression and the e¡ects
of cyclooxygenase inhibitors on wound healing upon
full-thickness incisions in mouse skin. Immunohisto-
chemical analysis revealed prominent expression of
cyclooxygenase isozymes in keratinocytes of the hyper-
plastic epithelium, with cyclooxygenase-1 immuno-
signals predominating in the suprabasal compartment
and cyclooxygenase-2 immunosignals spread through-
out the whole epidermis. Moreover, dendritic cells,
resembling Langerhans cells, as well as endothelial cells
and macrophages in the vicinity of or within the
granulation tissue were found to express both isozymes.
Inhibition of prostaglandin E2 synthesis by oral
administration of the cyclooxygenase-1-selective inhi-
bitor SC-560 or the cyclooxygenase-2-selective inhibi-
tor valdecoxib did not retard wound healing in mouse
skin macroscopically. Except for a slight transient retar-
dation of epithelialization early after wounding wound-
induced neoangiogenesis, collagen deposition, and the
restoration of tensile strength were not delayed by these
agents. Likewise, the nonselective inhibitor indometha-
cin had no e¡ect on the tensile strength of incisional
skin wounds. Key words: angiogenesis/cyclooxygenase/
epidermis/SC-560/valdecoxib. J Invest Dermatol 119:1189 ^1195,
2002
N
onsteroidal anti-in£ammatory drugs (NSAID) are
among the most commonly used pharmaceuti-
cals worldwide. The anti-in£ammatory e¡ect of
NSAID is thought to be mainly due to the inhi-
bition of cyclooxygenases (COX) (Vane, 1998).
COX are bifunctional enzymes catalyzing the ¢rst two steps in
prostanoid biosynthesis (Smith et al, 2000). Using arachidonic
acid as a substrate, the resulting endoperoxide prostaglandin
(PG)H2 is further converted by prostanoid synthases into the bio-
logically active prostanoids such as the prostaglandins PGE2,
PGF2a, PGD2, PGI2, and thromboxane A2 in a cell-type-speci¢c
manner.There are two COX isozymes, i.e., a constitutive COX-1
and an inducible COX-2 the expression of which is stimulated by
a wide variety of growth factors, cytokines, and hormones, in
particular in the course of in£ammatory processes (Williams
et al, 1999). A transient upregulation of COX-2 protein, but not
of COX-1, has been shown to occur upon super¢cial skin
wounding (Scholz et al, 1995). A permanent COX-2 overexpres-
sion has been found to be causally related to tumorigenesis (Neu-
fang et al, 2001). The anti-in£ammatory e¡ects of NSAID may
relate to an inhibition of COX-2 rather than of COX-1 (Smith
et al, 1998). Resolution of the X-ray crystal structure of both COX
isozymes (Picot et al, 1994; Luong et al, 1996) led to the develop-
ment of isozyme-selective inhibitors (Talley, 1999).
A major adverse e¡ect of conventional NSAID inhibiting both
COX-1 and COX-2 is injury to the gastric mucosa (Soll et al,
1991). In contrast, selective COX-2 inhibitors have been found
to be devoid of such side-e¡ects both in animals and humans
(Masferrer et al, 1994; Seibert et al, 1994; Chan et al, 1995; Laine
et al, 1999; Simon et al, 1999). There is nevertheless some concern
as to adverse e¡ects of COX-2 inhibitors on epithelial wound
healing as tissue damage is a particular strong inducer of COX-2
expression (Scholz et al, 1995; Kishimoto et al, 1998; Tessner et al,
1998).
To investigate the role of selective COX isozyme inhibition in
wound repair we have used the established model of acute inci-
sional wounding in the skin of mice. Repair of full-thickness
incisions was followed up for 28 d and re-epithelialization,
neovascularization of the wound bed, and collagen deposition as
well as the regain of tensile strength have been used as determi-
nants of the healing process. As shown here, neither COX
isozyme-selective inhibitors nor a nonselective COX inhibitor
exhibited any signi¢cant e¡ect on skin wound healing.
MATERIALS ANDMETHODS
Materials Control diet 5010 and diet supplemented with valdecoxib and
SC-560 were kindly supplied by Searle/Pharmacia (Skokie, IL) and stored
at 41C until use. Indomethacin was from Sigma (Deisenhofen, Germany).
Goat polyclonal anti-COX-1 (SC1754) and anti-COX-2 (SC1745) anti-
bodies, peroxidase-conjugated goat anti-rabbit IgG, goat anti-rat IgG, and
donkey anti-goat IgGwere purchased from Santa Cruz (Heidelberg, Germany),
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puri¢ed monoclonal rat anti-mouse CD31 (PECAM-1) antibody from
Becton Dickinson (Heidelberg, Germany), and rabbit anti-mouse Ki-67
from Dianova (Hamburg, Germany). Enzyme-linked immunosorbent
assay-bovine serum albumin, goat serum, and Masson’s trichrome staining
kit were purchased from Sigma, PGE2 enzyme immunoassay from
Cayman (Ann Arbor, MI). Rompun and Ketanest were purchased from
Bayer Vital (Leverkusen, Germany) and from Park Davis (Berlin,
Germany), respectively, nylon sutures were from Resorba (Nˇrnberg,
Germany).
Animals Twelve week old female NMRI mice (an outbred strain from
RCC, Fˇllinsdorf, Switzerland) were used. The animals were kept under
an arti¢cial day^night rhythm and were fed diet (see below) and water ad
libitum. All animal experiments were approved by the Regierungs-
prLsidium Karlsruhe, Germany (¢le number 059/2000).
Feeding of animals Groups of animals were fed rodent diet 5010,
diet 5010 supplemented with 500 p.p.m. valdecoxib or 64 p.p.m. SC-560,
altromin diet (Lage, Germany), or altromin diet supplemented with 16
p.p.m. indomethacin. The drug-supplemented diets were given 7 d before
surgery and during the course of the study.
Analysis of blood plasma for COX-inhibitor levels Plasma samples
(0.3 ml) were collected 7 d after beginning the treatment with valdecoxib
diet and SC-560 diet or control diet. To this end, plasma was collected
from ¢ve animals per group, frozen immediately in liquid nitrogen, and
stored at 701C. Analysis of blood plasma levels was carried out as
described (Reddy et al, 2000).
Skin incisional wounding For histologic, immunohistochemical, and
prostaglandin analysis three to six animals per group and for the
determination of tensile strength and plasma levels of inhibitors ¢ve
animals per group were anesthetized by consecutive intraperitoneal
injections of Rompun and Ketanest (20 mg per kg and 100 mg per kg
body weight, respectively). The hair of the back skin was shaved with
electric clippers and skin was wiped once with 70% ethanol. In the
shaved area a single transverse full-thickness incision, 2 cm in length, was
made extending through epidermis and dermis to the panniculus carnosus.
Incisions were sealed with three interrupted nylon sutures spaced 0.5 cm
each. After wounding, mice were separated into individual cages for 3 d.
The wounds and general health of the animals were monitored daily for
up to 4 wk postsurgery. No complications were encountered. One biopsy
comprising the total wound area and 3 mm of nonwounded skin on each
side was collected from each animal, bisected in the center, and prepared
for histochemistry and immunohistochemistry at days 1, 2, 3, 7, 14, and 28
after injury. In matched controls similar areas of skin were excised from the
nonwounded back skin of each animal. For prostaglandin analysis wound
tissue was frozen immediately in liquid nitrogen and stored at ^801C until
extraction.
Histochemistry and immunohistochemistry For hematoxylin/eosin
and Masson’s trichrome stainings, skin was ¢xed in phosphate-bu¡ered
saline-bu¡ered 4% paraformaldehyde for 16 h before embedding into
para⁄n and 5 mm sections were then processed according to the
instructions of the supplier. For immunohistochemical staining
cryosections, 5 mm thick, were used to detect various antigens. COX
isozymes were immunodetected as described (Mˇller-Decker et al, 1998a;
Neufang et al, 2001). Ki-67, and CD31 immunostainings were performed
according to the same protocol, except that 1% enzyme-linked immuno-
sorbent assay^bovine serum albumin in phosphate-bu¡ered saline was
used as blocking solution and sections were ¢xed in acetone for 10 min.
Primary antibodies were diluted 1 : 50 (Ki-67), 1 : 100 (COX-1 and -2), or
1 : 200 (CD31), and peroxidase-conjugated secondary antibodies 1 : 100
in blocking solution. Development with diaminobenzidine was used for
visualization. Sections were counterstained with hematoxylin (Merck,
Darmstadt, Germany), dehydrated, and mounted with Eukitt (O. Kindler,
Freiburg, Germany). Specimens were examined by an Axioskop 2
microscope connected to an Axiocam camera using Axiovision software,
release 2.05 (Zeiss, Goettingen, Germany).
Quantitation of vessel density Vessel density in the wound bed was
determined by scanning the section at low magni¢cation (100), one
visual ¢eld each from the center to the left and right periphery
(equivalent to 3 mm2). Microvessel counts in this area were performed
at160 magni¢cation. According to a published procedure (Dellas et al,
1997), any endothelial cell cluster positive for CD31 and clearly separate
from an adjacent cluster was considered as a single vessel. At least six
wound beds (12 visual ¢elds) from three animals were counted. Results
are expressed as mean number of vessels7SD.
Determination of prostaglandin concentrations Immediately after
excision, biopsies were frozen in liquid nitrogen and then homogenized
with a dismembrator (Braun, Melsungen, Germany) in liquid nitrogen
and suspended in 2 ml of ice-cold ethanol. After thorough mixing for
30 s, the proteins were pelleted by centrifugation (10 min at 3000 g and
41C). Prostaglandins were extracted from the supernatant by solid phase
extraction. The pellet was dissolved in 8 M urea and used for the
measurement of protein concentration. Prostaglandin levels were
quantitated by means of a commercially available enzyme immunoassay
as previously described (Mˇller-Decker et al, 1995).
Measurement of tensile strength Seven or 15 d after wounding ¢ve
animals per group were killed and skin samples were immediately
prepared for the measurement of tensile strength. Analysis was performed
as previously described (Gorodetsky et al, 1988) with minor modi¢cations.
Brie£y, a rectangular piece of skin (2 5 cm) with the wound in the center
was excised. The samples were spread on ¢lter papers and cut per-
pendicularly across the wound into ¢ve 3 mm strips. These were kept
(up to 10 min at the most) in a humidi¢ed chamber until measurement.
For the determination of tensile strength the ¢lter paper was removed
from the central 4 cm of the strip. The individual strip was mounted on
to an Instron tensiometer model 5542 (Instron Corporation, Canton,
MA), leaving the central 2 cm of skin as the bridge between the upper
and lower jaws. Strain (g per area of skin)/stress (elongation) curves and
the breaking point of the samples were recorded. The area under the peak
of each record represents tensile strength, i.e., the total energy needed to
break the skin sample. The tensile strength of ¢ve strips per wound of
¢ve animals each (i.e., 25 records) was determined.
Statistics Data represent mean7SD. Using Student’s t test pr0.05 was
regarded as signi¢cant.
RESULTS
The incisional wound model mimics authentic surgical proce-
dures (Davidson, 1998). This model system was employed to
study COX isozyme expression in response to wounding and to
examine the e¡ects of the COX-2 selective inhibitor valdecoxib
(Talley et al, 2000) and the COX-1 selective inhibitor SC-560
(Smith et al, 1998) on re-epithelialization, angiogenesis, and col-
lagen deposition. The tensile strength of the healing wounds
was determined in the presence of the COX isozyme-selective
inhibitors and the nonselective COX inhibitor indomethacin
(Ferreira et al, 1971). Full-thickness 2 cm transverse incisions ex-
tending through epidermis and dermis to the panniculus carno-
sus were made on the back of mice at the age of 13 wk, i.e., when
the majority of hair follicles were in the resting phase. Animals
were fed with control diet or experimental diet containing 500
p.p.m. valdecoxib, 64 p.p.m. SC-560, or 16 p.p.m. indomethacin.
These doses corresponded to the anti-in£ammatory doses of SC-
560 (Smith et al, 1998), valdecoxib (Talley et al, 2000), and indo-
methacin (Masferrer et al, 1994). Inhibitor treatment was started 7
d before wounding resulting in steady-state plasma levels7SD of
91.0742.0 ng valdecoxib per ml and 18.579.2 ng SC-560 per ml
at the time point of wounding. Feeding of diets was continued
until collection of skin samples. The PGE2 content in the
wounded skin area was found to be strongly elevated at days 2
and 7 after surgery as compared with unwounded matched con-
trol tissue (Table I). Upon treatment with valdecoxib, SC-560, or
indomethacin wound-induced PGE2 levels were reduced by
75%, 50%, and 72% at day 2 and by 52%, 95%, and 93% at
day 7 after surgery indicating that both COX-2 and COX-1 con-
tributed to wound-induced prostaglandin synthesis albeit with
varying ratios in the course of healing. The e¡ects of the COX
isozyme-selective inhibitors on the gross appearance and progress
of wound healing were followed up by visual inspection and his-
tologic and immunohistochemical analysis on days 1, 2, 3, 7, 14,
and 28 after surgery.
Gross appearance and histology of incisional skin wounds
were not a¡ected upon treatment of mice with COX
isozyme-selective inhibitors Wounding-induced bleeding
time was similar in all groups. Irrespective of the treatment the
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tissue adjacent to the wound edges was swollen to a similar extent
at day 1 after wounding and sealing of the wounds by a
dehydrated crust became visible at day 2. The thin scab was
progressively lost and not retained longer than 7 d, except for
one wound of three in the group treated with valdecoxib.
Closure of the wounds at day 7 (Fig 1) and hair regrowth
covering the wounds at day 14, were similar in mice of all
treatment groups. Four weeks after surgery the wounds
appeared to be fully healed in all mice at least upon visual
inspection (Fig 1).
For histologic analysis wound tissues were collected from three
to six animals per group. In both inhibitor-treated and control
animals epidermal hyperplasia at the wound site was apparent
1 d after injury and persisted for about 2 wk. By day 3 all
wounds had re-epithelialized, but were still covered with a scab,
which had dropped o¡ in all but one wound at day 7 (Fig 4). At
that time the newly formed epidermis of control mice looked
mature, i.e., had developed a horny layer, whereas in wounds of
valdecoxib- and SC-560-treated animals this maturation process
seemed to be delayed (Fig 2D,F; see also Fig 4A^C). By day 14,
however, new epidermis of inhibitor-treated animals was
indistinguishable from controls (Fig 5A^C). At day 28 after
injury epidermis had re-established its normal thickness of one
basal cell layer and up to three suprabasal cell layers, including
stratum corneum independent of inhibitor treatment (Fig 3B,F).
Determination of the proliferation index by counting
interfollicular Ki-67-immunopositive keratinocytes in the
wound area, i.e., the wound edges plus immediately adjacent
¢elds (Fig 2G^L), was carried out 1, 2, 3, 7, 14, and 28 d after
wounding (Fig 2M). A representative immuno-histochemical
staining for Ki-67 is shown for day 2, i.e., the time point of
maximal proliferation (Fig 2G^L). Although slight di¡erences
of the proliferative indices of wound epithelium between
control and inhibitor-treated animals were observed at this time
point (and in the COX-1 inhibitor group at day 3) the overall
kinetics of Ki-67 expression was similar in all treatment groups
(Fig 2M).
Valdecoxib and SC-560 did not alter the wound-induced
COX isozyme expression Con¢rming earlier observations
(Mˇller-Decker et al, 1998b), COX-1 protein was found to be
expressed in individual keratinocytes as well as in dendritic cells
that morphologically resemble Langerhans cells of normal
epidermis. In control wounds COX-1 protein was located pre-
dominantly in the suprabasal compartment of the hyperplastic
epithelium as well as dendritic cells (Fig 3A). This pattern of
expression persisted during the ¢rst 2 wk of follow up. At day
28 after wounding the pattern of COX-1 expression was again
similar as in unwounded skin (Fig 3B).
COX-2 protein was barely detectable in keratinocytes of
normal interfollicular mouse epidermis, but prominent in outer
root sheath cells of anagen hair follicles, whereas outer root
sheath cells of telogen hair follicles were COX-2-negative (data
not shown). In wounded epidermis, however, COX-2 pro-
tein was found in keratinocytes throughout the hyperplastic
epithelium and in dendritic cells (Fig 3E). This pattern persisted
during the whole follow up, although expression decreased
towards day 28 after surgery when the morphology of
epidermis looked normal again. In addition, COX-2 protein was
found in the outer root sheath cells of anagen hair follicles and in
basal cells of associated sebaceous glands (Fig 3F). Furthermore,
both COX isozymes were found in endothelial cells of large
vessels as well as in macrophages in the vicinity of or within the
wound bed (Fig 3C^H). No changes in COX isozyme
expression were found in the presence of either the COX-1 or
the COX-2 inhibitor (data not shown).
COX isozyme-selective inhibition did not impair wound-
induced neovascularization Sproating of new capillaries
towards the wound space was examined by immuno-
histochemical staining of endothelial cells with CD31 antibody,
representatively shown in Fig 4(A^Cn) for specimens collected
7 d after wounding. In wounds of control mice blood vessel
density as assessed by counting CD31-microvessel clusters, was
maximal at days 7^14 and back to basal values at day 28 after
surgery (Fig 4D). Similar values were recorded for inhibitor-
treated mice, although vessel density was slightly increased in
wounds of valdecoxib-treated animals at day 7 (Student’s t test,
po0.05).
Collagen deposition was not a¡ected by COX isozyme-
selective inhibition In a ¢rst step, collagen deposition within
the wound bed was investigated by the Masson’s trichrome
procedure, which stains collagen ¢bers blue, cytoplasm red, and
nuclei dark blue. Staining of wound specimens revealed tiny
¢bers of collagen, the majority of which were arranged in a
parallel fashion throughout the wound bed 7 d after wounding
(data not shown). One week later collagen density had increased
and ¢bers were reorganized towards a net-like structure (Fig 5A^C,
An^Cn) but were still di¡erent from the basket-weave
organization of dermal collagen bundles in unwounded dermis.
According to microscopic inspection, collagen deposition and
cell density within the granulation tissue were not a¡ected by
COX inhibitor treatment (Fig 5An^Cn).
Restoration of the tensile strength was not impeded by
COX isozyme-selective and nonselective inhibitors. Tensile
strength of wounded skin re£ecting regain of epidermal strength,
¢brillar collagen deposition, as well as remodeling during the
course of wound healing was measured by means of a tensiometer.
Table I. Inhibition of PGE2 levels in incisional wounds by
valdecoxib, SC-560, and indomethacin treatment 2 d and 7 d
postwounding
PGE2 (pg per mg protein)7 SEM
Treatment 2 d 7 d
Control diet (unwounded) 18778 81715
Control diet (wounded) 2085079385 3997135
Valdecoxib (wounded) 54757118 192727
SC-560 (wounded) 113837774 2176
Indomethacin (wounded)a 9787122 149789
aTwo and 7 d after wounding control values were 35487546 and 20987955,
respectively, for the indomethacin experiment.
Wounded and unwounded control tissue (15mm2) from two to four animals
per group was snap-frozen, pulverized, and PGE2 levels were determined by an
enzyme immunoassay as described previously (Mˇller-Decker et al, 1995).
Figure1. Gross appearance and progress of wound healing on back
skin of mice fed control diet or diet supplemented with 500 p.p.m.
valdecoxib or 64 p.p.m. SC-560. Photographs were taken 7 and 28 d
after full thickness skin incisions were made.
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Samples were collected 7 and 15 d after surgery. Tensile strength
of unwounded skin was found to be 2.7^3.5 N. In animals fed the
control diet the wounds had regained about 15% and 50% of
original tensile strength within 7 and 15 d, respectively. Similar
values were recorded for valdecoxib- and indomethacin-treated
animals, whereas a slight transient increase of tensile strength
was measured upon SC-560 treatment (Fig 5D).
DISCUSSION
Using an established model (Davidson, 1998) we investigated the
e¡ect of acute incisional wounding on COX isozyme expression
and the e¡ect of COX inhibitors on the wound response in
mouse skin.
COX-1 was constitutively expressed to about the same extent
in normal and wounded epidermis but its cellular localization
was slightly di¡erent in the latter: whereas being detectable in
individual keratinocytes and dendritic cells throughout the
normal epithelium (Mˇller-Decker et al, 1998b), COX-1 protein
located predominantly to suprabasal keratinocytes of the
hyperplastic wound epithelium. This alteration persisted for at
least 2 wk. COX-2 being barely detectable in interfollicular epi-
dermis of unwounded skin (Mˇller-Decker et al, 1998b) was
found to be rapidly induced upon wounding and became
strongly expressed in keratinocytes and dendritic cells
Figure 2. Kinetics of re-epithelialization and proliferation in full-thickness incisional skin wounds.Mice were fed control diet (A,B,G,H) or diet
containing 500 p.p.m.valdecoxib (C,D,I,J) or 64 p.p.m.SC-560 (E,F,K,L) and analyzed 2 d (G^L), 3 d (A,C,E), and 7 d (B,D,F) after surgery. Specimens were
stained with anti-COX-2 antibodies (A^F) or anti-Ki-67 antibodies (G^L). The wound edges are marked with arrows (G,I,K). Epidermis (e), granulation
tissue (g), and eschar (es). Original magni¢cation:  630 (A^F, insert H),  160 (G^L). (M) Kinetics of proliferation in interfollicular wound epidermis.
Ki-67-immunopositive cells were counted in the wound center and the immediate neighboring ¢elds.Values represent mean7SD (nnp o 0.005, nnnp o
0.0005) according to Student’s t test, n¼ 6 sections or 24 microscopic ¢elds (original magni¢cation160)/group and time point.
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throughout the hyperplastic epithelium, in endothelial cells of
large vessels, and in macrophages within the wound bed. Some
COX-2 expressing keratinocytes were still detectable 28 d after
wounding, whereas the COX-1 expression pattern and epidermal
morphology looked normal at this time-point.
Similar observations have been reported for other epithelia.Thus,
in gastric epithelium of mice injured by acetic acid (Mizuno et al,
1997) and in trinitrobenzene sulfonic acid-induced colitis in rats
(Reuter et al, 1996) COX-1 expression remained essentially unaf-
fected, but disappeared in the mucosa adjacent to the ulcer crater
in chronic gastric ulceration of rat stomach (Schmassmann et al,
1998). On the other hand, COX-2 was rapidly induced upon
injury in the stomach of mice and rats (Mizuno et al, 1997; Gretzer
et al, 1998) or upon induction of colitis in rat colon (Reuter et al,
1996). Cellular localization of COX-2 in gastric mucosa and
colon, however, was di¡erent from that found in skin wounds:
epithelial cells were the major COX-2-positive cell type in skin,
whereas in injured gastric mucosa (Schmassmann et al, 1998) and
colonic epithelium (Reuter et al, 1996), COX-2 expression was
predominant in nonepithelial cells, including macrophages, en-
dothelial cells, and ¢broblasts. Thus, the induction of COX-2
protein appears to be a common feature of acute and chronic
epithelial wounds with the expression persisting during the
healing process.
Figure 3. Localization of COX isozymes in incisional wounds by
immunohistochemistry with goat anti-COX-1 (A^D) and goat
anti-COX-2 (E^H) antibodies. Wound specimens were collected from
control animals at various time points: 24 h (A,E,C,G), 7 d (D,H), and 28
d (B,F). Note COX-1 expression in suprabasal cells of interfollicular epider-
mis (A), dendritic cells (A, insert), endothelial cells (C), and macrophages
(D). Note COX-2 expression in basal as well as suprabasal interfollicular
keratinocytes (E), the outer root sheath of hair follicles and sebaceous gland
epithelium (F), dendritic cells (E, insert), endothelial cells (G), as well as
macrophages (H). Original magni¢cation: 630.
Figure 4. Localization of CD31-positive vessels in incisional
wounds from animals fed control diet or diet supplemented with
valdecoxib or SC-560.Wound specimens were collected 7 d postsurgery
from animals fed control diet (A,An), valdecoxib diet (B,Bn), or SC-560
diet (C,Cn), and processed for immunohistochemistry using rat anti-
CD31 antibody. Original magni¢cation: 100 (A^C),  630 (An^Cn).
(D) Vessel density as function of time after incision. Microvessel density
was determined in the wound centers as shown under A^C by counting
CD31-immunopositive endothelial clusters. Values represent mean 7 SD
(nnpo 0.05), according to Student’s t test, n ¼ 6 sections or 12 microscopic
¢elds/group and time point.
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Wounding led to a strong increase of the prostaglandin level
in skin. This response was strongly inhibited by both
COX-isozyme-selective inhibitors and the nonselective inhibitor
indomethacin, indicating that both isozymes contributed to
wound-induced prostaglandin synthesis albeit with varying ratios
during the course of healing. A similar suppression of prostaglan-
din synthesis has also been reported for colonic and gastric injury
upon treatment with nonselective COX-inhibitors, such as indo-
methacin or diclofenac, the selective COX-1 inhibitor SC-560, or
COX-2 inhibitors, including NS398, celecoxib, and L745337
(Reuter et al, 1996; Lesch et al, 1998; Gretzer et al, 2001).
Notwithstanding the similarities of epithelial COX isozyme
expression and activity in the various wound models opposite ef-
fects of COX-2 inhibitors on healing were observed. Regarding
dermal aspects of the healing process in this study the kinetics of
collagen deposition and the restoration of the mean tensile
strength were similar in incisional skin wounds of normal and
valdecoxib-treated animals. Wound-induced neovascularization
was transiently increased rather than inhibited by valdecoxib.
This result suggests a di¡erent sensitivity of wound- and tumor-
associated angiogenesis towards COX-2 inhibitors, which have
been shown to suppress the latter (Masferrer et al, 2000; Leahy
et al, 2002). Concerning epidermis a slightly decreased prolifera-
tive index early after wounding and a somewhat delayed matura-
tion indicate a transient impairment of wound epithelialization
by COX-2 inhibition.
Similarly, the COX-2-selective inhibitors PD138387 and cele-
coxib did not impair the healing of acute acetic acid-induced gas-
tric ulcer in rats when applied in anti-in£ammatory doses (Lesch
et al, 1998). Moreover, neither celecoxib nor valdecoxib did impair
wound healing as monitored by collagen deposition into subcu-
taneously implanted sponges in rats (Muscara et al, 2000). In con-
trast, two other COX-2-selective inhibitors, i.e., NS398 (Mizuno
et al, 1997) and L745337 (Reuter et al, 1996; Schmassmann et al,
1998) were shown to delay ulcer healing in acute and chronic gas-
tric mucosa and colonic epithelium of rats when given in anti-
in£ammatory doses. In chronic gastric ulcers this delay correlated
with a suppression of PGE2 levels, decreased epithelial cell prolif-
eration in the ulcer margin, and reduced microvessel density in
the ulcer bed (Schmassmann et al, 1998). PGE2 levels and angio-
genesis in carrageenin-induced granulation tissue have also been
found to be suppressed by NS398 (Ghosh et al, 2000). These re-
sults gave rise to the hypothesis that the apparently contradictory
e¡ects of NS398 and L745337 on wound healing may be related
to other e¡ects than inhibition of COX-2 activity (Lesch et al,
1998).
On the other hand, selective inhibition of COX-1 has been
shown to exacerbate injury in acid-challenged gastric mucosa
(Gretzer et al, 2001) but did not a¡ect (except for a slight impair-
ment of wound epithelialization) neovascularization, collagen de-
position, and the breaking strength of acute incisional wounds in
mouse skin as shown here. The simultaneous inhibition of both
COX isozymes has also been shown to aggravate gastric injury in
rat mucosa (Wallace et al, 2000; Gretzer et al, 2001) and to impair
healing of ischaemic wounds in rat skin (Quirinia and Viidik,
1997). Again such an e¡ect was not observed with acute incisional
wounds in rat (Haws et al, 1996) and not in mouse skin as shown
here. Provided that these animal data can be extrapolated to hu-
mans, postoperative administration of COX inhibitors are not
expected to impair healing of acute incisional wounds that are
the major lesion generated in surgery. Whether or not selective
COX inhibitors a¡ect chronic venous leg ulcers where macro-
phages and endothelial cells are the main cellular sources of both
COX-1 and COX-2 remains to be clari¢ed (Abd-El-Aleem et al,
2001).
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